| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
Top-line results for SLIM-1™, the first-in-human Phase 1 trial of NPM-139, Vivani's miniature, ultra-long-acting semaglutide implant under development for chronic weight management, are anticipated for announcement later this week |
| 30 Oct 2026 |
8-K: Regulation FD Disclosure
As previously disclosed, Vivani Medical, Inc. (“Vivani”) entered into a definitive agreement and plan of merger among its wholly owned subsidiary Cortigent, Inc. (“Cortigent”), ClearOne, Inc. (“ClearOne”), and CLRO Merger Sub, Inc. (“Mer... |
| 29 Oct 2026 |
8-K: Regulation FD Disclosure
Vivani Medical, Inc. (“Vivani”) from time to time presents, and/or distributes to the investment community at various industry and other conferences, slide presentations to provide updates and summaries of its business. A copy of these s... |
| 16 Sep 2026 |
8-K: Regulation FD Disclosure
As previously disclosed, Vivani Medical, Inc. (“Vivani”) entered into a definitive agreement and plan of merger among its wholly owned subsidiary Cortigent, Inc. (“Cortigent”), ClearOne, Inc. (“ClearOne”), and CLRO Merger Sub, Inc. (“Mer... |
| 17 Aug 2026 |
8-K: Regulation FD Disclosure
Vivani Medical, Inc. (“Vivani”) from time to time presents, and/or distributes to the investment community at various industry and other conferences, slide presentations to provide updates and summaries of its business. A copy of these s... |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
All participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management; top-line data expected in November 2026 |
| 06 Aug 2026 |
8-K: Regulation FD Disclosure
Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management |
| 16 Jul 2026 |
8-K: Regulation FD Disclosure
Vivani Medical, Inc. (the “Company” or “Vivani”) made a presentation at the Emerging Growth Conference in New York on Wednesday, July 15, 2026 at 4:10 p.m. Eastern Time. A copy of a slide presentation that Dr. Adam Mendelsohn, Vivani’s C... |
| 07 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
Schedule 5.25 Pre-Existing Contractual Obligations Requiring Equity Issuances |
| 30 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders +1 more
The name of the plan is the Amended and Restated Vivani Medical, Inc. 2022 Omnibus Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Vivani ... |
| 04 Jun 2026 |
8-K: Regulation FD Disclosure
Vivani Medical, Inc., or Vivani, will make a presentation at the Jefferies Global Healthcare Conference in New York on Thursday, June 4, 2026 at 11:05 a.m. Eastern. A copy of a slide presentation that Dr. Adam Mendelsohn, Vivani’s Chief ... |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Initiation of SLIM-1™ clinical trial, a Phase 1 study of NPM-139, a semaglutide implant under development for chronic weight management, on track for mid-year 2026 |
| 26 Mar 2026 |
8-K: Results of Operations and Financial Condition
Successful completion of first-in-human study LIBERATE-1 paired with preclinical proof of concept data for a semaglutide implant advance NPM-139, miniature, ultra long-acting semaglutide implant under development for chronic weight manag... |
| 27 Jan 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This Placement Agency Agreement (the “Agreement”) sets forth the terms upon which ThinkEquity LLC (“ThinkEquity” or the “Placement Agent”) shall be engaged by Vivani Medical Inc., a corporation formed under the laws of the state of Delaw... |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Company plans to initiate Phase 1 clinical study of semaglutide implant for chronic weight management in the first half of 2026 and parallel investments in studies to enable rapid initiation of Phase 2 dose-ranging study, pending Phase 1... |
| 28 Oct 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This Placement Agency Agreement (the “Agreement”) sets forth the terms upon which ThinkEquity LLC (“ThinkEquity” or the “Placement Agent”) shall be engaged by Vivani Medical Inc., a corporation formed under the laws of the state of Delaw... |
| 03 Oct 2025 |
8-K: Regulation FD Disclosure; Other Events
The Company expects to reestablish and announce a new record date as soon as possible |
| 17 Sep 2025 |
8-K: Other Events
Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology. It is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind |
| 09 Sep 2025 |
8-K: Regulation FD Disclosure
Vivani Medical, Inc. (the “Company”) from time to time presents and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates and summaries of its business. These slides a... |
Loading...